SNY Jan 2025 47.000 call
| Previous close | 5.60 |
| Open | 5.60 |
| Bid | 4.90 |
| Ask | 5.60 |
| Strike | 47.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.60 - 5.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 151 |
ZacksSanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
GlobeNewswirePress Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncolog
ReutersBristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.
